ICP-332 not checked
Beijing InnoCare Pharma Tech Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
3 active
7 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Atopic Dermatitis, Chronic Spontaneous Urticaria (CSU), Non Segmental Vitiligo
- Main trialPhase 3
- “A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis”In the company’s words, NCT06775860 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis
- UpadacitinibAbbVie · Phase 3
- OPA-15406Otsuka · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 3
- GX-03Turn Therapeutics · Phase 2/3
- VC005Jiangsu vcare pharmaceutical technology co., LTD · Phase 3
- StapokibartKeymed Biosciences Co.Ltd · Phase 3
Coming up3
- 25 NovPhase 3 trial completes · ClinicalTrials.gov
- Sep 2028Phase 2/3 trial completes · ClinicalTrials.gov
- Apr 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 13 NovStatus changed: Recruiting to Completed · ClinicalTrials.gov NCT07251998
- 13 NovCompletion date moved: 2026-10 to 2026-10-30 · ClinicalTrials.gov NCT07251998
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 25 Nov 2026 | ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | |
| Phase 2/3Recruiting | Sep 2028 | Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria | |
| Phase 2/3Recruiting | Apr 2029 | ICP-332 in Subjects With Non-segmental Vitiligo | |
| Phase 2Unknown | 30 Jul 2023 | Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis | |
| Phase 2Completed | 30 Oct 2026 | Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 1Completed | 30 Jan 2022 | A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects | |
| Phase 1Completed | 8 Nov 2024 | Phase I Study of ICP-332 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026